{
  "meta": {
    "title": "42_Asthma_Copd",
    "url": "https://brainandscalpel.vercel.app/42-asthma-copd-35bbe2b4.html",
    "scrapedAt": "2025-11-30T12:28:45.315Z"
  },
  "questions": [
    {
      "text": "Which among the following about idiosyncratic asthma is false?",
      "choices": [
        {
          "id": 1,
          "text": "Presents in childhood"
        },
        {
          "id": 2,
          "text": "Normal IgE levels"
        },
        {
          "id": 3,
          "text": "Commonly have concomitant nasal polyps"
        },
        {
          "id": 4,
          "text": "Negative skin test for common inhalant allergens"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Idiosyncratic </strong>or <strong>intrinsic asthma</strong> does not present in childhood. It typically shows a later onset of disease (<strong>adult-onset asthma</strong>).</p><hr><h3>Related Pearl: Extrinsic vs Intrinsic asthma</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Extrinsic asthma</strong></td>\n<td><strong>Intrinsic asthma</strong></td>\n</tr>\n<tr>\n<td>Other names</td>\n<td>Atopic/ allergic asthma</td>\n<td>Non-atopic/ non-allergic/ idiosyncratic asthma</td>\n</tr>\n<tr>\n<td>Associated with&nbsp;</td>\n<td>Atopy, drug or food allergy (past or family history)</td>\n<td>Samter&rsquo;s triad (asthma + aspirin sensitivity + sinus disease with recurrent nasal polyps)</td>\n</tr>\n<tr>\n<td>Onset</td>\n<td>Childhood</td>\n<td>Adult</td>\n</tr>\n<tr>\n<td>Inflammation</td>\n<td>Eosinophil mediated</td>\n<td>Neutrophil mediated</td>\n</tr>\n<tr>\n<td>IgE levels</td>\n<td>&uarr; IgE (type 1 hypersensitivity)</td>\n<td>Normal IgE (negative skin prick test)</td>\n</tr>\n<tr>\n<td>Most common trigger</td>\n<td>Dermatophagoides (House mite)</td>\n<td>\n<p>Superantigen -&nbsp;<br /><em>S. aureus</em> enterotoxin</p>\n</td>\n</tr>\n<tr>\n<td>Response to inhaled corticosteroids</td>\n<td>Responds well&nbsp;</td>\n<td>\n<p>Decreased short term response</p>\n</td>\n</tr>\n<tr>\n<td>Prognosis</td>\n<td>Good</td>\n<td>Bad</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9705",
      "difficulty": "medium"
    },
    {
      "text": "A 36-year-old woman presented with wheezing after taking aspirin for a headache. Which of the following is true regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Raised serum IgE levels"
        },
        {
          "id": 2,
          "text": "Positive skin test for inhaled allergens"
        },
        {
          "id": 3,
          "text": "Associated with nasal polyps"
        },
        {
          "id": 4,
          "text": "A type of extrinsic asthma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of<strong> aspirin-sensitivity asthma</strong>. It&nbsp;is closely associated with <strong>nasal polyps</strong>.</p>\n<p>Aspirin-exacerbated respiratory disease (AERD), also known as <strong>Samter&rsquo;s triad</strong> or<strong> aspirin-sensitive asthma</strong>. It is a chronic medical condition that consists of:</p>\n<ul>\n<li><strong> Intrinsic asthma</strong></li>\n<li>Recurrent sinus disease with nasal polyps</li>\n<li>Sensitivity to aspirin and other NSAIDs</li>\n</ul>\n<p>It has <strong>normal serum IgE</strong> levels&nbsp;and a <strong>negative skin</strong>&nbsp;<strong>test</strong> for inhaled allergens.</p><hr><h3>Related Pearl: Extrinsic vs Intrinsic asthma</h3><table>\n<tbody>\n<tr>\n<td><strong>Component</strong></td>\n<td><strong>Extrinsic asthma</strong></td>\n<td><strong>Intrinsic asthma</strong></td>\n</tr>\n<tr>\n<td>Other names</td>\n<td>Atopic/ allergic asthma</td>\n<td>Non-atopic/ non-allergic/ idiosyncratic asthma</td>\n</tr>\n<tr>\n<td>Associated with&nbsp;</td>\n<td>Atopy, drug or food allergy (past or family history)</td>\n<td>Samter&rsquo;s triad (asthma + aspirin sensitivity + sinus disease with recurrent nasal polyps)</td>\n</tr>\n<tr>\n<td>Onset</td>\n<td>Childhood</td>\n<td>Adult</td>\n</tr>\n<tr>\n<td>Inflammation</td>\n<td>Eosinophil mediated</td>\n<td>Neutrophil mediated</td>\n</tr>\n<tr>\n<td>IgE levels</td>\n<td>&uarr; IgE (type 1 hypersensitivity)</td>\n<td>Normal IgE (negative skin prick test)</td>\n</tr>\n<tr>\n<td>Most common trigger</td>\n<td>Dermatophagoides (House mite)</td>\n<td>\n<p>Superantigen -&nbsp;<br /><em>S. aureus</em> enterotoxin</p>\n</td>\n</tr>\n<tr>\n<td>Response to inhaled corticosteroids</td>\n<td>Responds well&nbsp;</td>\n<td>\n<p>Decreased short term response</p>\n</td>\n</tr>\n<tr>\n<td>Prognosis</td>\n<td>Good</td>\n<td>Bad</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9709",
      "difficulty": "easy"
    },
    {
      "text": "What is the best way to diagnose patients with suspected bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Chest X-ray"
        },
        {
          "id": 2,
          "text": "Skin test for inhaled allergens"
        },
        {
          "id": 3,
          "text": "FEV1 values"
        },
        {
          "id": 4,
          "text": "Demonstration of reversible obstruction"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The best way to diagnose bronchial asthma is by the <strong>demonstration of reversible obstruction </strong>of the airways.&nbsp;Following the administration of an inhaled beta 2 agonist, a <strong>12%</strong> and <strong>200 ml increase</strong> in the FEV1 demonstrates the reversibility of airway obstruction.</p>\n<p>Options A and B: Chest X-ray and skin test for inhaled allergens are not diagnostic of bronchial asthma.</p>\n<p>Option C: FEV1 values are measured to calculate FEV1/FVC ratio to diagnose any obstructive pathology and not specifically for asthma alone.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3406",
      "difficulty": "medium"
    },
    {
      "text": "A young woman is rushed to ED due to wheezing and gasping for breath. She is unable to speak in full sentences. Her husband reports that she has had a cough with fever for 3 days. On examination, PR- 121/min, RR- 32/min, and has cyanosis. Her ABG analysis and chest X-ray are given below. What is the likely diagnosis?<div class='question-desc-html'><p>ABG analysis:&nbsp;</p>\n<p>pH- 7.48</p>\n<p>PaO2- 64 mmHg</p>\n<p>PaCO2- 32 mmHg</p>\n<p>HCO3- 25 mEq/L</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Acute respiratory distress syndrome"
        },
        {
          "id": 2,
          "text": "Asthma with impending failure"
        },
        {
          "id": 3,
          "text": "Acute pneumothorax"
        },
        {
          "id": 4,
          "text": "Acute severe asthma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario of <strong>dyspnea</strong>, <strong>tachycardia</strong> along with the ABG analysis suggestive of <strong>respiratory alkalosis</strong> and chest-Xray showing <strong>hyperinflated lungs</strong> is pointing to a diagnosis of&nbsp;<strong>acute severe asthma</strong>. A history of cough with fever is indicating a probable <strong>respiratory infection</strong> to have triggered the asthma exacerbation.&nbsp;</p>\n<p>Features of acute severe asthma vs asthma with impending respiratory failure:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Acute severe asthma</strong></td>\n<td><strong>Asthma with impending respiratory failure</strong></td>\n</tr>\n<tr>\n<td>Dyspneic, speaks in words</td>\n<td>Mute patient</td>\n</tr>\n<tr>\n<td>Agitated patient</td>\n<td>Silent / confused patient</td>\n</tr>\n<tr>\n<td>Heart rate &gt; 120 /min, tachycardia</td>\n<td>Relative bradycardia</td>\n</tr>\n<tr>\n<td>Pulsus paradoxus present</td>\n<td>Pulsus paradoxus absent (due to respiratory muscle fatigue)</td>\n</tr>\n<tr>\n<td>Accessory muscles of respiration used</td>\n<td>Paradoxical breathing is seen</td>\n</tr>\n<tr>\n<td>Loud wheeze throughout the respiration</td>\n<td>Silent chest</td>\n</tr>\n<tr>\n<td>Peak expiratory flow rate &lt; 40 ml/min</td>\n<td>Peak expiratory flow rate &lt; 25 ml/min</td>\n</tr>\n<tr>\n<td>Respiratory alkalosis</td>\n<td>Respiratory acidosis</td>\n</tr>\n<tr>\n<td>Hyperventilation leading to low or normal PaCO2</td>\n<td>Normal or rising PaCO2</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: The X-ray is not showing the features of<strong>&nbsp;ARDS</strong> and&nbsp;<strong>pneumothorax</strong>, hence they are ruled out as the right options.&nbsp;</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Asthma is often under-diagnosed and under-treated, particularly in low- and middle-income countries. World Asthma Day is held annually on the first Tuesday in May to ensure availability of and access to effective, quality-assured medications. &ldquo;Asthma care for All&rdquo; is the theme for the 2023, promoting the development &amp; implementation of  effective asthma management programs in all countries.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">Asthma is often under-diagnosed and under-treated, particularly in low- and middle-income countries. World Asthma Day is held annually on the first Tuesday in May to ensure availability of and access to effective, quality-assured medications. &ldquo;Asthma care for All&rdquo; is the theme for the 2023, promoting the development &amp; implementation of effective asthma management programs in all countries.</span></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/080872a670a842b0b3b3b4f511f2526a.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3403",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is not recommended in the treatment of patients with bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Sodium cromoglycate"
        },
        {
          "id": 2,
          "text": "Zafirlukast"
        },
        {
          "id": 3,
          "text": "Roflumilast"
        },
        {
          "id": 4,
          "text": "Dupilumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Roflumilast</strong> is a phosphodiesterase-4 inhibitor used in the treatment of <strong>COPD</strong>, not asthma.</p>\n<p><strong>Drugs used</strong> in the <strong>treatment of bronchial asthma</strong></p>\n<p><strong>Bronchodilators</strong></p>\n<ul>\n<li>Beta-2 sympathomimetics: Salmeterol, formoterol</li>\n<li>Methylxanthines: Theophylline, aminophylline</li>\n<li>Anticholinergics: Ipratropium bromide, tiotropium bromide</li>\n</ul>\n<p><strong>Anti-inflammatory </strong></p>\n<ul>\n<li>Corticosteroids (inhalational): Beclomethasone, budesonide, fluticasone</li>\n<li>Corticosteroids (systemic): Prednisolone, hydrocortisone</li>\n<li>Mast cell stabilizers: <strong>Sodium cromoglycate</strong>, ketotifen</li>\n<li>Leukotriene antagonists: Montelukast, <strong>zafirlukast</strong></li>\n<li>Anti-IgE: Omalizumab</li>\n<li>Anti-IL5: Mepolizumab, reslizumab</li>\n<li>Anti-IL4 receptor:&nbsp;<strong>Dupilumab</strong></li>\n</ul><hr><h3>Related Pearl: Treatment of Asthma based on severity of symptoms (GINA-2022)</h3><p>Asthma management - GINA 2022</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3349e17dd3a64530b8cda3c9732af613x1280x3702.792665726375.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3407",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false regarding leukotriene modifiers in the management of bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Ketotifen belongs to this group"
        },
        {
          "id": 2,
          "text": "Associated with Churg- Strauss syndrome"
        },
        {
          "id": 3,
          "text": "Protect against exercise-induced asthma"
        },
        {
          "id": 4,
          "text": "Diminishes nocturnal symptoms of asthma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ketotifen</strong> is an example of a&nbsp;<strong>mast cell stabilizer</strong>, not leukotriene modifiers.</p>\n<p><strong>Leukotriene modifiers&nbsp;</strong>are a&nbsp;group of agents used for mild persistent asthma. They <strong>block LT1-receptors</strong> thus causing reduced eosinophilic inflammation and causing bronchodilator. They include <strong>montelukast</strong>, <strong>zafirlukast</strong>, and<strong> zileuton</strong>.</p>\n<p>Leukotriene modifiers are less effective than inhaled corticosteroids (ICS) in controlling asthma. They are used as add-on therapy in some patients whose asthma is not controlled with low doses of ICS.</p>\n<p><strong>Churg&ndash;Strauss syndrome</strong> (CSS) is a rare granulomatous small vessel vasculitis, that affects the heart, kidneys, peripheral nerves, etc. It occurs against a background of long-standing asthma and marked peripheral eosinophilia. Several cases of CSS are associated with the use of <strong>montelukast</strong> and <strong>zafirlukast</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3408",
      "difficulty": "medium"
    },
    {
      "text": "Treatment of choice for patients with type 2 brittle asthma is:",
      "choices": [
        {
          "id": 1,
          "text": "Inhaled Salbutamol"
        },
        {
          "id": 2,
          "text": "Subcutaneous salbutamol"
        },
        {
          "id": 3,
          "text": "Subcutaneous terbutaline"
        },
        {
          "id": 4,
          "text": "Subcutaneous adrenaline"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The<strong> treatment</strong> of choice for <strong>type II brittle asthma</strong> is <strong>subcutaneous adrenaline</strong>.</p>\n<p><strong>Brittle asthma</strong> is a type of <strong>severe asthma</strong> where patients have very serious and often, life-threatening attacks despite appropriate therapy. It is of two types:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type 1</strong></td>\n<td><strong>Type 2</strong></td>\n</tr>\n<tr>\n<td>\n<p>A persistent pattern of variability in PEFR (peak expiratory flow rate) readings</p>\n</td>\n<td>\n<p>Generally normal or near-normal PEFR readings but few unpredictable exacerbations occur without an obvious trigger</p>\n</td>\n</tr>\n<tr>\n<td>Oral steroids, infusion of bronchodilators, and dietary exclusion of allergens may be helpful</td>\n<td>&nbsp;Respond only to subcutaneous epinephrine</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9951",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following class of drugs cannot be used in the treatment of patients with bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "IL-4 receptor antagonists"
        },
        {
          "id": 2,
          "text": "Anti–IL-5 antibodies"
        },
        {
          "id": 3,
          "text": "Anti IgE antibody"
        },
        {
          "id": 4,
          "text": "IL- 1 antagonist"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The treatment options for asthma do not include IL-1 antagonists&nbsp;(anakinra). <strong>Anakinra</strong> is used in the treatment of <strong>rheumatoid arthritis.&nbsp;</strong></p>\n<p>Cytokines mediating airway inflammation in asthma:&nbsp;<strong>IL-4, IL-5, IL-13, TGF-&beta;</strong>,&nbsp;and chemokines.</p>\n<p><strong>Omalizumab</strong> is a monoclonal antibody <strong>against IgE</strong>. It is available for the treatment of children &ge;6 years of age with documented allergen-induced asthma that is inadequately controlled by inhaled corticosteroids. &nbsp;</p>\n<p>The new treatment options for asthma under clinical trial are:&nbsp;</p>\n<ul>\n<li><strong>Mepolizumab:</strong> anti&ndash;IL-5 antibody</li>\n<li><strong>Benralizumab:&nbsp;</strong>anti&ndash;IL-5 receptor antibody</li>\n<li><strong>Dupilumab:</strong> anti&ndash;IL-4 receptor antibody</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9648",
      "difficulty": "medium"
    },
    {
      "text": "A 6-year-old asthmatic boy is rushed to the casualty. He is not responding to the commands and is having fast shallow breathing.  On auscultation, the chest is silent and paradoxical breathing is present. ABG analysis shows respiratory acidosis. What is the best step in management for him?",
      "choices": [
        {
          "id": 1,
          "text": "Hyperbaric oxygen therapy"
        },
        {
          "id": 2,
          "text": "MDI with salbutamol and corticosteroids"
        },
        {
          "id": 3,
          "text": "Immediate endotracheal intubation"
        },
        {
          "id": 4,
          "text": "Intravenous magnesium sulfate"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of <strong>severe asthma</strong> with impending <strong>respiratory failure</strong>. The&nbsp;best step in the management is <strong>immediate endotracheal intubation</strong>.</p>\n<p>Features of asthma with impending respiratory failure are:</p>\n<ul>\n<li>Mute or confused patient</li>\n<li><strong>Paradoxical breathing</strong></li>\n<li><strong>Silent</strong>&nbsp;<strong>chest</strong> on auscultation&nbsp;</li>\n<li>Relative bradycardia</li>\n<li>Peak expiratory flow rate (PEFR) &lt;25ml/min</li>\n<li>Arterial blood gas analysis shows<strong> respiratory acidosis</strong>.</li>\n</ul>\n<p>Option A: Hyperbaric oxygen is given in CO poisoning and high altitude pulmonary edema.</p>\n<p>Option B: MDI with salbutamol and corticosteroids is only useful for acute severe asthma.</p>\n<p>Option D: Intravenous magnesium sulfate is not routinely used.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3402",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is false regarding COPD?",
      "choices": [
        {
          "id": 1,
          "text": "Increased resistance is seen in airways ≤2 mm diameter"
        },
        {
          "id": 2,
          "text": "Changes in large airways cause cough and sputum"
        },
        {
          "id": 3,
          "text": "Ventilation-perfusion mismatching is seen"
        },
        {
          "id": 4,
          "text": "Rise in post bronchodilator FEV1>12%"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The rise in post-bronchodilator FEV1&gt;12% is a feature of asthma, not COPD. It suggests reversible airflow obstruction. </p>\n<p>Chronic obstructive pulmonary disease (<strong>COPD</strong>) is a chronic respiratory disease characterized by the presence of <strong>airflow obstruction</strong> that is <strong>partially reversible</strong>.</p>\n<p><strong>Cigarette smoking</strong> is the <strong>most common cause</strong> of COPD. Cigarette smoke exposure affects large airways, small airways, and alveoli:</p>\n<ul>\n<li>Changes in<strong> large airways </strong>cause <strong>cough </strong>and<strong> sputum</strong></li>\n<li>Changes in <strong>small airways</strong> (<strong>≤2mm</strong>) and alveoli are responsible for physiologic alterations</li>\n</ul>\n<p>The major site of<strong> increased resistance</strong> in most individuals with COPD is in airways ≤2 mm diameter.</p>\n<p>Characteristic cellular changes include goblet cell metaplasia. <strong>Goblet cells</strong> are mucus-secreting cells that replace surfactant-secreting Club cells.</p>\n<p>Nonuniform ventilation and <strong>ventilation-perfusion mismatching</strong> are characteristic of COPD.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9953",
      "difficulty": "easy"
    },
    {
      "text": "What happens to Reid index in patients with chronic bronchitis?",
      "choices": [
        {
          "id": 1,
          "text": "Increases"
        },
        {
          "id": 2,
          "text": "Decreases"
        },
        {
          "id": 3,
          "text": "Remains same"
        },
        {
          "id": 4,
          "text": "Increases initially and then decreases"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Reid index</strong> is <strong>increased</strong> in chronic bronchitis.</p>\n<p>Reid index is the ratio of the thickness of the mucous gland layer to the thickness of the bronchial wall.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b41a1fc073494da7b25ccb1d8eb442bdx1280x1391.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3414",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following findings is least likely to be seen in patients with COPD?",
      "choices": [
        {
          "id": 1,
          "text": "Barrel chest"
        },
        {
          "id": 2,
          "text": "Hoover's sign"
        },
        {
          "id": 3,
          "text": "Cyanosis"
        },
        {
          "id": 4,
          "text": "Clubbing"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Clubbing is not a sign of COPD. Its presence should trigger the investigation of the causes of clubbing, particularly<strong> lung cancer</strong>.</p>\n<p><strong>Signs of COPD</strong>:</p>\n<ul>\n<li aria-level=\"1\">Signs of respiratory distress\n<ul>\n<li aria-level=\"1\"><strong>Tripod posture </strong>- facilitates the use of accessory muscles of respiration</li>\n<li aria-level=\"1\">Pursed lip breathing - seen in emphysema</li>\n<li aria-level=\"1\"><strong>Central cyanosis</strong></li>\n</ul>\n</li>\n<li>Signs of cachexia\n<ul>\n<li>Severe weight loss</li>\n<li>Bitemporal wasting</li>\n</ul>\n</li>\n<li>Signs of hypercapnia (<strong>type 2 respiratory failure</strong>) - more common in chronic bronchitis</li>\n<li aria-level=\"1\"><strong>Barrel-shaped chest </strong>- increase in the anteroposterior diameter</li>\n<li>Enlarged lung volumes</li>\n<li aria-level=\"1\"><strong>Positive Hoover's sign </strong>- paradoxical inward movement of the chest during inspiration</li>\n<li aria-level=\"1\">Early inspiratory coarse crackles  </li>\n<li aria-level=\"1\">Normal vesicular breath sounds of reduced-intensity with bilaterally prolonged expiration</li>\n<li aria-level=\"1\"><strong>Blue bloaters - </strong>cyanotic (blue) and edematous (bloaters), <strong>chronic bronchitis</strong> predominant features</li>\n<li aria-level=\"1\"><strong>Pink puffers</strong> - thin, non-cyanotic (pink) at rest, and severely dyspneic (puffers), <strong>emphysema</strong> predominant features </li>\n</ul>\n<p><strong>Causes of clubbing</strong>:</p>\n<ul>\n<li><strong>Pulmonary</strong></li>\n<ul>\n<li>Bronchogenic carcinoma</li>\n<li>Lung abscess, empyema, bronchiectasis</li>\n<li>Chronic interstitial pneumonitis</li>\n<li>Cystic fibrosis</li>\n<li>Sarcoidosis</li>\n</ul>\n<li><strong>Gastrointestinal </strong></li>\n<ul>\n<li>Inflammatory bowel disease</li>\n<li>Sprue</li>\n<li>Neoplasms - esophagus, liver, bowel</li>\n</ul>\n<li><strong>Cardiovascular</strong></li>\n<ul>\n<li>Cyanotic congenital heart disease</li>\n<li>Subacute bacterial endocarditis</li>\n<li>Aortic aneurysm</li>\n<li>Arteriovenous fistula</li>\n</ul>\n<li><strong>Endocrine </strong>\n<ul>\n<li>Hyperthyroidism (Grave’s disease)</li>\n</ul>\n</li>\n</ul>\n<p>The image below shows the characteristic <strong>tripod posture</strong> in a patient with COPD. </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f427aee2ac5f4865be9410361221c7bex960x1280.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3412",
      "difficulty": "medium"
    },
    {
      "text": "A 28-year-old coal miner presented with breathing difficulties. He reported that his symptoms get aggravated at work. His chest X-ray showed features of emphysema. On evaluation, he was found to have an α1-antitrypsin deficiency. Which pathological type of emphysema is most likely present in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Centri-acinar"
        },
        {
          "id": 2,
          "text": "Pan-acinar"
        },
        {
          "id": 3,
          "text": "Irregular"
        },
        {
          "id": 4,
          "text": "Para-septal"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The pathological type most likely to be present in this patient is&nbsp;<strong>pan-acinar emphysema.&nbsp;</strong>This type is commonly seen in patients with&nbsp;<strong>&alpha;1-antitrypsin deficiency</strong>.</p><hr><h3>Related Pearl: Types of emphysema</h3><p><strong>Emphysema</strong> is classified according to its anatomic distribution within the lobule.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Area involved</strong></td>\n<td><strong>Other features</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Centriacinar (most common)</strong></p>\n</td>\n<td>\n<ul>\n<li>Central part of acinus (respiratory bronchiole)</li>\n<li>Upper lobes of lung</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Commonly seen in<strong> smokers</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Panacinar</strong></td>\n<td>\n<ul>\n<li>Entire acinus (respiratory bronchiole + alveoli)</li>\n<li>Lower lobes of lung</li>\n</ul>\n</td>\n<td>\n<ul>\n<li aria-level=\"1\">Commonly seen in young <strong>non-smokers</strong></li>\n<li aria-level=\"1\">Associated with <strong>&alpha;-1 antitrypsin deficiency</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Paraseptal</strong></td>\n<td>\n<ul>\n<li>Distal part of acinus (alveoli)</li>\n<li>Subpleural region</li>\n</ul>\n</td>\n<td>\n<ul>\n<li aria-level=\"1\">Commonly seen in young adults&nbsp;</li>\n<li aria-level=\"1\">Increased risk for <strong>spontaneous pneumothorax&nbsp;</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Irregular</strong></td>\n<td>\n<ul>\n<li>Focal and irregular involvement of acinus</li>\n<li>Areas of the lung near scar tissue&nbsp;</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Not usually seen in COPD</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a93fe0d6352f4bddb79cbafb63f956e0x1280x3586.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3411",
      "difficulty": "easy"
    },
    {
      "text": "An elderly man is being evaluated for exertional dyspnea, cough, and weight loss. His chest CT is given below. What is it suggestive of?",
      "choices": [
        {
          "id": 1,
          "text": "Emphysematous lung"
        },
        {
          "id": 2,
          "text": "Atypical pneumonia"
        },
        {
          "id": 3,
          "text": "Calcified granulomas"
        },
        {
          "id": 4,
          "text": "Interstitial fibrosis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>CT scan</strong> shows <strong>emphysematous lungs</strong>, with reduced parenchymal markings and focal areas of low attenuation. This represents the emphysematous destruction of the lung, indicative of<strong> hyperinflation</strong>.</p>\n<p>Radiographic studies in COPD show:</p>\n<ul>\n<li>Emphysematous bullae</li>\n<li>A paucity of parenchymal markings</li>\n<li>Hyperlucency suggests the presence of emphysema</li>\n<li>Increased lung volumes and<strong> flattening </strong>of the<strong> diaphragm</strong> suggest hyperinflation</li>\n</ul>\n<p>Option B: Atypical pneumonia shows patchy bilateral ground-glass opacities.</p>\n<p>Option C: Calcified granulomas are seen as dense, bright nodules.</p>\n<p>Option D: Interstitial fibrosis shows a honeycomb pattern of the lung parenchyma as shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2a4c2e6ed9534c45ae3752d9ca23c784x246x157.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/34ead242e43644ef935196bd29c60e7f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3417",
      "difficulty": "easy"
    },
    {
      "text": "A 55-years old chronic smoker presented with chronic cough with expectoration. He has been having similar episodes for the past 2 years. He also reported that he had to rest every few minutes while walking due to breathlessness. Pulmonary function tests showed FEV1/FVC of  0.5 and FEV1  of 50%. Which of the following is not a feature of the given condition?",
      "choices": [
        {
          "id": 1,
          "text": "Irreversible airflow limitation"
        },
        {
          "id": 2,
          "text": "Affects small airway disease"
        },
        {
          "id": 3,
          "text": "Decrease in residual volume"
        },
        {
          "id": 4,
          "text": "Associated with ineffective repair of elastin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical picture is highly suggestive of chronic obstructive pulmonary disease(<strong>COPD</strong>). An <strong>increase</strong> in the <strong>residual volume</strong> is a feature of COPD.</p>\n<p>COPD is defined as a chronic respiratory disease&nbsp;characterized by the presence of <strong>airflow obstruction</strong> that is <strong>partially reversible</strong>.&nbsp;</p>\n<p>COPD is the clinical expression of <strong>abnormalities</strong> of <strong>airways</strong> and/or <strong>alveoli</strong> and includes:&nbsp;</p>\n<ul>\n<li><strong>Emphysema&nbsp;</strong>is defined pathologically as the abnormal and <strong>permanent dilation</strong> of <strong>airways</strong> distal to the terminal bronchiole, along with the destruction of their walls.</li>\n<li><strong>Chronic bronchitis </strong>is&nbsp;defined clinically as the presence of <strong>persistent cough</strong> with <strong>sputum production</strong> on most of the days for <strong>&ge;3 months</strong> in <strong>2 consecutive years</strong>.&nbsp;</li>\n<li><strong>Small airways diseases&nbsp;</strong>are conditions affecting<strong> airways</strong> of<strong> &le;2 mm</strong>, resulting in inflammation and narrowing of the same.&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3409",
      "difficulty": "medium"
    },
    {
      "text": "Chest X-ray of an emphysematous patient is as shown.  What is the best investigation to measure his lung volume?",
      "choices": [
        {
          "id": 1,
          "text": "Body plethysmography"
        },
        {
          "id": 2,
          "text": "Gas dilution"
        },
        {
          "id": 3,
          "text": "Fractional exhaled NO"
        },
        {
          "id": 4,
          "text": "DLCO"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Body plethysmography is the best investigation to measure lung volume in an emphysematous patient with<strong> bullous lesions</strong> as seen on the X-ray.</p>\n<p>To measure absolute lung volumes, two techniques are used:</p>\n<ol>\n<li><strong>Body plethysmography:&nbsp;</strong>It is used to measure the volume of any gas containing space in the thorax <strong>including&nbsp;bullae.</strong> It is accurate in both obstructive and restrictive diseases.</li>\n<li><strong>Inert gas dilution technique:&nbsp;</strong>It is used to measure the volume of regions that are well ventilated which <strong>excludes</strong> trapped gas or bullae. It is accurate in restrictive diseases only.</li>\n</ol>\n<p>The amount of gas trapped in bullae can be measured by subtracting lung volumes measured by inert gas dilution technique from lung volume measured by body plethysmography.</p>\n<p>Fractional exhaled nitric oxide (F<sub>E</sub>NO) is a<strong> non-invasive test</strong>&nbsp;used in the diagnosis and monitoring of bronchial asthma. NO levels are <strong>increased</strong> in asthmatics&nbsp;and related to the eosinophilic inflammation in the airways.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c6cb2450349c4f668a25e9ca1e9b2a76.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3416",
      "difficulty": "medium"
    },
    {
      "text": "A 66-year-old chronic smoker presents with progressive shortness of breath and chronic cough. On examination, he has a barrel chest and has pursed-lip breathing. Hyperresonance and inspiratory wheezes are heard. Pulmonary functions are likely to reveal all of the following, except:",
      "choices": [
        {
          "id": 1,
          "text": "Decreased vital capacity"
        },
        {
          "id": 2,
          "text": "Increased diffusion capacity for carbon monoxide"
        },
        {
          "id": 3,
          "text": "Increased total lung capacity"
        },
        {
          "id": 4,
          "text": "Decreased FEV1/FVC ratio"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical diagnosis is suggestive of <strong>COPD</strong> and the underlying pathological change is likely to be<strong> emphysema. </strong>It&nbsp;is associated with <strong>a decreased</strong> diffusion capacity for carbon monoxide (<strong>DLCO</strong>).</p>\n<p>Emphysema&nbsp;is defined pathologically as the <strong>abnormal</strong> and <strong>permanent dilation</strong> of <strong>airways</strong> distal to the terminal bronchiole, along with the <strong>destruction</strong> of their <strong>walls</strong>.&nbsp;This leads to hyperinflation due to air trapping and impaired diffusion of gases.</p>\n<p><strong>Pulmonary function tests in COPD:</strong></p>\n<ul>\n<li>TLC: Normal or increased</li>\n<li>FEV1: Decreased (&lt;80% predicted)</li>\n<li>FVC: Decreased</li>\n<li>FEV1/FVC: Decreased</li>\n<li>DLCO: Decreased</li>\n</ul>\n<p><strong>Diseases associated with lowered DLCO:</strong></p>\n<ul>\n<li>Emphysema</li>\n<li>Interstitial Lung disease</li>\n<li>Primary pulmonary hypertension</li>\n</ul>\n<p>Note - <strong>Bronchial asthma</strong> is associated with an <strong>increased DLCO.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3413",
      "difficulty": "medium"
    },
    {
      "text": "The Gold's criteria for severe COPD are:",
      "choices": [
        {
          "id": 1,
          "text": "FEV1/FVC <0.7 and FEV1 ≥ 30%"
        },
        {
          "id": 2,
          "text": "FEV1/FVC <0.7 and  FEV1 < 30%"
        },
        {
          "id": 3,
          "text": "FEV1/FVC<0.7 and  FEV1< 20%"
        },
        {
          "id": 4,
          "text": "FEV1/FVC<0.7 and FEV1 ≥ 50%"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Gold's criteria for severe COPD (stage III) are <strong>FEV1/FVC &lt;0.7</strong> and<strong> FEV1 &ge; 30%&nbsp;</strong>but &lt;50%</p>\n<p>The severity of COPD is assessed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>GOLD Stage</strong></p>\n</td>\n<td>\n<p><strong>Severity </strong></p>\n</td>\n<td>\n<p><strong>Spirometry </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>I</p>\n</td>\n<td>\n<p>Mild</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 &ge;80% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>II</p>\n</td>\n<td>\n<p>Moderate</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 &ge;50% but &lt;80% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>III</p>\n</td>\n<td>\n<p>Severe</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 &ge;30% but &lt;50% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>IV</p>\n</td>\n<td>\n<p>Very severe</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 &lt;30% predicted</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: FEV1/FVC and FEV1 predicted are measured after the administration of a bronchodilator.</p><p>Recent update:&nbsp;<strong>PRISm</strong> refers to a group of COPD patients with <strong>apparent normal spirometry</strong>, but with <strong>emphysema (as seen on radiographic evaluation)</strong> and a wide range of lung function impairment.&nbsp; These patients have a <strong>higher mortality risk</strong> as compared to other COPD patients. The possible risk factors are exposure to smoking, high BMI, and reduced total lung capacity. Spirometry findings are <strong>low to normal FEV1</strong>, and <strong>normal FEV1/FVC ratio</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1630",
      "difficulty": "hard"
    },
    {
      "text": "A patient presents to the OPD with shortness of breath. He reports walking slower than his peers due to breathlessness. He has had two hospitalizations for similar complaints this year. His post-bronchodilator PFTs are FEV1/FVC < 0.55 and FEV1 55%.  Under what category would he be classified based on GOLD criteria?",
      "choices": [
        {
          "id": 1,
          "text": "Moderate COPD, Group C"
        },
        {
          "id": 2,
          "text": "Moderate COPD, Group E"
        },
        {
          "id": 3,
          "text": "Severe COPD, Group A"
        },
        {
          "id": 4,
          "text": "Severe COPD, Group D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This patient belongs to <strong>moderate COPD</strong>, <strong>group E</strong> category.</p>\n<p>The severity of COPD assessed by the Global Initiative for Lung Disease (GOLD) is classified as:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>GOLD Stage</strong></p>\n</td>\n<td>\n<p><strong>Severity </strong></p>\n</td>\n<td>\n<p><strong>Spirometry </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>I</p>\n</td>\n<td>\n<p>Mild</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 ≥80% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>II</p>\n</td>\n<td>\n<p>Moderate</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 ≥50% but &lt;80% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>III</p>\n</td>\n<td>\n<p>Severe</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 ≥30% but &lt;50% predicted</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>IV</p>\n</td>\n<td>\n<p>Very severe</p>\n</td>\n<td>\n<p>FEV1/FVC &lt;0.7 and FEV1 &lt;30% predicted</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p>According to <strong>GOLD 2023 guidelines</strong>, COPD patients are classified into Group <strong>A, B, or E</strong> based on the <strong>severity of dyspnoea,</strong> <strong>frequency of exacerbations and hospitilization</strong>. Dyspnoea may be assessed using the modified MRC Dyspnoea scale or COPD Assessment Test (CAT score)</p>\n<table>\n<tbody>\n<tr>\n<td>&gt;=2 moderate exacerbations or &gt;=1 leading to hospitalisation</td>\n<td>\n<p>Group E:<br />                        <strong> LABA+LAMA</strong></p>\n<p>consider LABA+LAMA+ICS* if blood eosinophil count &gt;=300</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<table>\n<tbody>\n<tr>\n<td>0 or 1 moderate exacerbation (not leading to hospital admissions)</td>\n<td>\n<p>Group A: mMRC 0-1, CAT&lt;10</p>\n<p>               <strong> Bronchodilator</strong></p>\n</td>\n<td>\n<p>Group B: mMRC &gt;=2, CAT &gt;=10</p>\n<p>         <strong> LABA + LAMA*</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>* single inhaler therapy maybe more convenient and effective than multiple inhalers</p>\n<p>ICS - inhaled corticosteroids<br />LAMA - Long-acting Muscarinic Antagonists<br />LABA - Long-acting Beta Agonists</p>\n<p><strong>Modified MRC (mMRC) dyspnoea scale:</strong></p>\n<ul>\n<li>0- Breathless only with strenuous exercise</li>\n<li>1- Breathless when hurrying on a level or walking up a hill</li>\n<li>2- Walks slower than peers or has to stop for breath when walking on level</li>\n<li>3- Stops for breath after walking about 100m or for a few minutes</li>\n<li>4- Breathless at rest</li>\n</ul>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3415",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false regarding acute exacerbations in COPD patients?",
      "choices": [
        {
          "id": 1,
          "text": "May not be accompanied with fever"
        },
        {
          "id": 2,
          "text": "Viral infection is a common precipitating factor"
        },
        {
          "id": 3,
          "text": "Glucocorticoids are contraindicated"
        },
        {
          "id": 4,
          "text": "May present with congestive heart failure"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Glucocorticoids</strong> are used during an <strong>exacerbation of COPD</strong>. They <strong>hasten recovery</strong> and reduce the chances of future exacerbations.</p>\n<p>Exacerbations are episodes of <strong>increased dyspnoea and cough</strong>, with a change in the amount and character of sputum. They are often <strong>triggered by an infection</strong> with one-third of cases having a viral etiology.&nbsp;They <strong>may or may not </strong>have other signs of illness such as <strong>fever</strong>, myalgias, and sore throat.&nbsp;In severe cases, they may present with pneumonia and<strong> congestive heart failure</strong>.</p>\n<p>Note: While oral glucocorticoids are contraindicated in long-term treatment due to side effects, they are used for acute exacerbation of COPD.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3419",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old male patient who is a known case of COPD presented with acute exacerbation and is admitted to the ICU. Which of the following statements is correct with regards to the initial management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Non-Invasive PPV should be given"
        },
        {
          "id": 2,
          "text": "Invasive PPV should be given"
        },
        {
          "id": 3,
          "text": "IV corticosteroids should be administered"
        },
        {
          "id": 4,
          "text": "Permissive hypercapnia is allowed"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Non-invasive positive pressure ventilation </strong>(NIPPV) should be the <strong>first</strong> mode of ventilation used in COPD patients with acute respiratory failure provided there are <strong>no absolute contraindications. </strong>This approach improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and enhances overall survival outcomes.</p>\n<p><strong>Invasive positive pressure ventilation</strong> is only considered after <strong>failure</strong> of NIPPV, resulting in severe respiratory distress, life threatening hypoxemia, severe hypercarbia and/or acidosis, markedly impaired mental status, <strong>respiratory arrest</strong> or<strong> hemodynamic instability</strong> (Option B).</p>\n<p>Apart from NIPPV, <strong>short-acting inhaled beta 2 agonists </strong>(albuterol, salbutamol) with or without <strong>short-acting anticholinergics</strong> (ipratropium) and <strong>Long-acting anticholinergics </strong>(tiotropium) are recommended as the initial bronchodilators. <strong>Maintenance</strong> therapy with long-acting beta 2 agonists (formoterol) must be started as soon as possible.</p>\n<p><strong>Systemic corticosteroids </strong>are useful in the treatment of acute exacerbations of COPD as they reduce airway inflammation and improve lung function over time. However, the effects are not immediate. NIPPV on the other hand provides<strong> immediate relief </strong>to the patient and reduces the work of breathing. Therefore, it would not be the best choice in this case. (Option C)</p>\n<p><strong>Antibiotics</strong> can also be considered, as they reduce duration of hospitalisation. Treatment is given for <strong>5 days. </strong></p>\n<p><strong>Permissive hypercapnia </strong>refers to a ventilation strategy where tidal volume is reduced in order to avoid hyperinflation-associated lung trauma. It is not preferred at the initial presentation. It is only permitted once invasive PPV is started following NIPPV failure (Option D) </p>\n<p>An<strong> exacerbation of COPD </strong>is defined as an event characterized by dyspnea and/or cough and sputum that worsen over &lt; 14 days. Exacerbations of COPD are often associated with <strong>increased</strong> <strong>local</strong> and <strong>systemic</strong> <strong>inflammation</strong> caused by airway infection, pollution, or other insults to the lungs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0880",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old obese chronic smoker is rushed to the ER with difficulty in breathing and a productive cough. He has a past history of two similar episodes this year. On examination, RR- 34/min, with use of accessory muscles and central cyanosis is present. ABG is as shown. Chest X-ray shows increased vascular markings. What is the best initial step of management?<div class='question-desc-html'><p>ABG Analysis:</p>\n<p>pH- 7.33</p>\n<p>PaO2- 50 mmHg</p>\n<p>PaCO2- 48 mmHg</p>\n<p>HCO3&oline;- 27 mEq/L</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Low flow humidified oxygen"
        },
        {
          "id": 2,
          "text": "High  flow humidified oxygen"
        },
        {
          "id": 3,
          "text": "Salbutamol and budesonide nebulisation"
        },
        {
          "id": 4,
          "text": "Slow infusion of theophylline"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario along with the ABG and X-ray findings is suggestive of <strong>acute exacerbation of COPD</strong> with respiratory failure. The best initial step of management is&nbsp;<strong>low-flow</strong> <strong>humidified</strong> <strong>oxygen.</strong></p>\n<p>Oxygen supplementation is a crucial component of acute therapy. Administering O2 should target a <strong>SpO2- 88-92%</strong> or <strong>PaO2- 60-70 mmHg</strong>. This helps to minimize the risk of worsening hypercapnia with excess supplemental oxygen.</p>\n<p>The given ABG shows<strong> respiratory acidosis</strong> as <strong>PaCO2 &gt;45 mmHg</strong>, and<strong> pH&lt;7.35</strong>. In respiratory acidosis, a trial of non-invasive ventilation is given. Hence, low-flow humidified oxygen is the first step in management.</p>\n<p>Option B: High flow oxygen causes dryness, crusting epistaxis, and damages the lung hence not used.&nbsp;</p>\n<p>Option C: Salbutamol and budesonide nebulization are not effective as initial management in exacerbation of COPD with respiratory failure.</p>\n<p>Option D: Methylxanthines are not recommended in the management of acute exacerbations due to their side effect profiles.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9715",
      "difficulty": "medium"
    },
    {
      "text": "In patients with which of the following conditions is NIPPV contraindicated?",
      "choices": [
        {
          "id": 1,
          "text": "COPD"
        },
        {
          "id": 2,
          "text": "Central hypoventilation syndrome"
        },
        {
          "id": 3,
          "text": "Cardiovascular instability"
        },
        {
          "id": 4,
          "text": "Chest wall disorders"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Noninvasive positive-pressure ventilation (<strong>NIPPV</strong>) is contraindicated in <strong>cardiovascular instability</strong>. NIPPV&nbsp;can impede venous filling of the heart, decrease cardiac output, and worsen/precipitate hypotension. Moreover, in unstable states with impending cardiovascular collapse,<strong> invasive ventilation</strong> is preferred.</p>\n<p><strong>Indications of NIPPV:</strong></p>\n<ul>\n<li>Apnea - central and obstructive</li>\n<li>Central hypoventilation syndrome</li>\n<li>Neuromuscular and chest wall disorders</li>\n<li>Respiratory failure - PaCO<sub>2&nbsp;</sub>&gt;45 mmHg</li>\n</ul>\n<p><strong>Contraindications of NIPPV:</strong></p>\n<ul>\n<li><strong>Cardiovascular instability</strong></li>\n<li>Impaired mental status or inability to cooperate</li>\n<li>Copious secretions or the inability to clear secretions</li>\n<li>Craniofacial abnormalities</li>\n<li>Trauma precluding effective fitting of the mask</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3420",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is not used in the long-term treatment of COPD patients?",
      "choices": [
        {
          "id": 1,
          "text": "Theophylline"
        },
        {
          "id": 2,
          "text": "Azithromycin"
        },
        {
          "id": 3,
          "text": "Oral glucocorticoids"
        },
        {
          "id": 4,
          "text": "N Acetylcysteine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Oral glucocorticoids</strong> are not used in the long-term treatment of COPD because of an <strong>unfavorable </strong>benefit/risk ratio.</p>\n<p>Chronic use of glucocorticoids is associated with significant side effects, including osteoporosis, weight gain, cataracts, glucose intolerance, and increased risk of infection.</p>\n<p><strong>Treatment of COPD:</strong></p>\n<ul>\n<li>Smoking cessation</li>\n<li>Anticholinergic agents- Ipratropium bromide</li>\n<li>Beta Agonists-&nbsp;Long-acting inhaled &beta; agonists, such as salmeterol or formoterol are commonly used.&nbsp;</li>\n<li>Methylxanthines- <strong>theophylline</strong> produces improvements in expiratory flow rates and vital capacity.&nbsp;</li>\n<li>Phosphodiesterase inhibitors - roflumilast is used when FEV1&lt;50%.&nbsp;</li>\n<li>Antibiotics- macrolides like <strong>azithromycin</strong> reduce exacerbations when used over one year</li>\n<li><strong><em>N</em>-acetylcysteine</strong> has been used in patients with COPD for both its mucolytic and antioxidant properties</li>\n<li>Oxygen therapy</li>\n</ul>\n<p><strong>Non-pharmacologic therapies:</strong></p>\n<ul>\n<li>Lung volume reduction surgery</li>\n<li>Lung transplantation</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3418",
      "difficulty": "medium"
    }
  ]
}